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Abstract 
Context: Dyspnea is one of the most common and distressing symptoms that occurs in terminal cancer patients. 
However, there are no existing treatment guidelines for this condition in China.
Objective: This single‑center, retrospective, observational study aimed to compare the efficacy of using morphine, 
methylprednisolone, or aminophylline to relieve the symptom of breathlessness in patients with advanced malignant 
tumors and to investigate the safety of these regimens during the treatment of dyspnea.
Methods: Between August 2011 and January 2015 we retrospectively reviewed the medical records of 343 termi‑
nally ill cancer patients with dyspnea who received morphine, methylprednisolone, or aminophylline. The therapeutic 
effect of each treatment by means of visual analogue scale (VAS) scores was assessed and compared. Statistical meth‑
ods included Chi square and analysis of variance tests. Differences were considered significant when P < 0.05.
Results: VAS scores after treatment were (16.82 ± 10.89), (25.72 ± 15.03), and (31.95 ± 16.00) points in the morphine, 
methylprednisolone, and aminophylline group, respectively. These differences were found to be significantly different 
(P < 0.05). The effectiveness ratings were 86.44, 62.16, and 49.12%, respectively (P < 0.05).
Conclusions: We found that morphine subcutaneous injection for advanced cancer patients with dyspnea was 
safe and typically more effective than methylprednisolone or aminophylline. Therefore, morphine treatment could 
significantly improve the quality of life in terminal cancer patients with short life expectancies who are experiencing 
shortness of breath.
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Background
Dyspnea, or breathlessness, is a subjective sensation 
described as uncomfortable or unpleasant labored 
breathing (air hunger) (Williams 2006). It is a devastat-
ing symptom that frequently occurs in advanced cancer 
patients. In advanced cancer, patients with any tumor, 
regardless of its primary site, may experience breathless-
ness. However, it is the most common in primary pul-
monary carcinomas and in patients with metastatic lung 
disease (Parshall et al. 2012). Almost 50–70% of patients 
with advanced cancer experience intractable dyspnea 
in the last 6  weeks, and dyspnea is the main symptom 
in more than 20% of patients within their final 48  h of 
life (Williams 2006; Parshall et al. 2012; Navigante et al. 
2006). Symptoms such as loss of appetite, fatigue, pain, 
and dyspnea reduce the quality of life (QoL) in cancer 
patients (Polanski et  al. 2016). These symptoms usually 
become gradually aggravated as the tumor progression.
Assessment of dyspnea, as presented in the published 
medical literature, follows a pattern similar to that of pain. 
However, all of the objective data, such as respiratory 
rate, arterial blood gases, and oxygen saturation, cannot 
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be used to quantitatively measure dyspnea. Therefore, 
assessing dyspnea relies on subjective measures, and the 
patient’s subjective self-report of breathlessness is the 
most valid and reliable indicator of its presence (Thomas 
and von Gunten 2002; Mancini and Body 1999). Respira-
tory depression severely impairs the quality of life in these 
patients, and is usually accompanied by anxiety, depres-
sion, fear, and even panic (Polanski et  al. 2016). These 
extremely  unpleasant  feelings further exacerbate the 
problem and immensely reduce the patient’s self-esteem 
and self-confidence. The development of standardized 
treatments for cancer pain has received considerable 
attention throughout the world (Caraceni et  al. 2012). 
However, in contrast to pain, breathlessness in terminally 
ill cancer patients is often not taken seriously and is fre-
quently poorly managed in China (Lai et al. 2007).
The most effective measures to alleviate dyspnea are 
to address the underlying cause(s) of the breathlessness, 
such as resolving infection, controlling tumor growth, 
correcting anemia, and draining malignant pleural effu-
sions (Williams 2006; Dy et al. 2008). Nevertheless, there 
is often no discernable treatable cause or patients are not 
eligible for etiological treatment due to their poor clinical 
state and overall health. Therefore, symptomatic treat-
ment is often necessary, and palliative care then focuses 
on the relief of suffering and on symptom control.
At present, morphine sulfate is internationally recom-
mended as the first-line therapy for cancer-related dysp-
nea (Ben-Aharon et  al. 2008, 2012). However, in China, 
primary interventions, including oxygen, methylpred-
nisolone, antiasthmatic drugs and benzodiazepine are 
often used to alleviate the symptoms of breathlessness in 
patients with advanced cancer. At the same time, mor-
phine may be used for cancer-related dyspnea in termi-
nally ill cancer patients, although many physicians and 
patients are reluctant to use morphine because of the 
concern for respiratory depression and the lack of com-
prehensive understanding about morphine.
Currently, there are only few high-quality, large-sam-
ple randomized controlled trials (RCTs) that assess the 
effects of morphine in the palliation of cancer-related 
breathlessness (Barnes et  al. 2016). Therefore, we retro-
spectively reviewed the medical records to evaluate the 
efficacy of using morphine to alleviate dyspnea sensa-
tions during the last 6 weeks of life in terminally ill can-
cer patients. To our knowledge, this is the first report to 
compare morphine, methylprednisolone, and aminophyl-
line therapy for patients with cancer-related breathless-
ness. The aim of this retrospective study was to provide 
significant information for clinical use and to improve 
our understanding of how beneficial/safe morphine may 
be for the treatment of cancer-related breathlessness in 
China.
Methods
Study design and patient population
A single-center, retrospective study was conducted in 
the department of Oncology, at Shanghai Ninth People’s 
Hospital, School of Medicine, Shanghai Jiao Tong Uni-
versity from August 2011 to January 2015. This study 
was approved by the Regional Ethics Committee of our 
hospital and the study complied with the Declaration of 
Helsinki. The patient’s information was anonymized and 
de-identified prior to analysis. Patients with advanced, 
stage III or IV cancer undergoing palliative treatment 
(alleviating the suffering and improving the life quality of 
patients) were eligible to participate in the study. Patients 
with advanced malignant tumors were confirmed by clin-
ical and imaging diagnosis. Demographic patient- and 
disease-related data, such as the type and dose of drugs, 
visual analogue scale scores, side effects during admis-
sion were evaluated and documented by the physician in 
charge at our palliative care unit, including all clinically 
relevant laboratory parameters.
We retrospectively selected patients who met the fol-
lowing criteria: (1) those that were at least 18 years old, 
(2) those that were diagnosed pathologically with cancer, 
(3) those that had provided the subjective self-report of 
moderate-to-severe dyspnea, such as uncomfortable, dis-
tressful, or labored breathing, (4) those with a serum cre-
atinine concentration within twice the normal range, (5) 
those with a life expectancy less than one month, and (6) 
those undergoing medicine intervention for dyspnea.
Patients were excluded if they met any of the follow-
ing criteria: (1) had a serious renal or hepatic failure 
(biochemically and/or clinically detected), (2) had active 
or uncontrolled chronic obstructive pulmonary disease 
(COPD) and serious lung infection, (3) were diagnosed 
with hemoglobin saturation by pulse oximetry (SaO2) 
<85%, (4) had superior vena cava syndrome (SVCS), (5) 
had non-compensated congestive heart failure, or 6) had 
a contraindication to morphine, benzodiazepine drugs, 
and hormones.
Treatment regimen
All eligible patients complaining of shortness of breath 
in bed received non-pharmacological support (oxygen 
therapy using nasal prongs at a rate of 2–6  L/min) as 
the foundation of treatment. According to the treatment 
received, we divided patients into the three groups as fol-
lows. In the morphine group, opioid-naïve patients were 
given 5  mg morphine subcutaneously, and opioid-toler-
ant patients were injected subcutaneously with 10% of 
the total opioid taken in the previous 24 h. In the methyl-
prednisolone group, 40 mg methylprednisolone in 100 ml 
normal saline was administered intravenously by drip for 
30 min. In the aminophylline group, 0.25 g aminophylline 
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with 5% glucose injection was administered intravenously 
by drip for 30 min.
Assessment
As is the case with pain, adequate assessment of dyspnea 
depends on self-report. A 100 mm visual analogue scale 
(VAS) was used to quantify breathlessness. The VAS 
scores were performed according to standard procedures. 
VAS is a measurement apparatus that tries to measure a 
characteristic or attitude that is believed to range across a 
continuum of values and cannot easily be directly meas-
ured (Pianosi et al. 2016). Operationally, a VAS is usually 
a horizontal line, 100  mm in length, anchored by word 
descriptors at each end. Anchors are “no breathless-
ness’’ at 0 mm and “worst imaginable breathlessness” at 
100 mm (Gould et al. 2001). The patient makes a mark on 
a 100-mm line with descriptors at each end correspond-
ing to the extent of their symptom before and after treat-
ment. Intensity of breathlessness was recorded by our 
palliative care unit before using any drugs and 1 h after 
one dose. Dyspnea relief was considered effective when 
the VAS numerical value decreased by more than 50%. 
The study’s principal endpoint was the effective rate of 
the intervention. Additional endpoints included the fre-
quency and severity of medication-related side effects. 
After 1 h of a single-dose, adverse effects were assessed 
and documented on a daily basis.
Statistical analysis
Descriptive statistics including frequencies, means, 
standard deviation (SD), medians, and ranges were used 
to examine the distribution of measures as appropriate. 
The Pearson’s Chi squared test was undertaken to exam-
ine bivariate associations between categorical variables, 
and analysis of variance (ANOVA) was undertaken to 
examine the associations between categorical and contin-
uous variables. The data were reported as mean SD. The 
P-values cited were derived from a two-tailed test, and P 
values less than 0.05 were considered statistically signifi-
cant. All calculations were performed with SPSS software 
version 19.0 (SPSS, Inc., Chicago, IL, USA).
Results
Patients characteristics
Information was collected from patient medical records; 
between August 2011 and January 2015, 343 cancer 
patients with moderate to severe dyspnea were enrolled in 
this study and were divided into three groups. 118 patients 
were treated with morphine. 111 patients were treated 
with methylprednisolone. 114 patients were treated 
with aminophylline. The average age of the patients was 
53.32 ± 18.29 years old (range 22–79 years). 174 patients 
were male and 169 patients were female. Overall, 125 
of 343 (36.44%) patients had lung cancer, 96 (27.99%) 
had breast cancer, 46 (13.41%) had colorectal cancer, 41 
(11.95%) had gastric cancer, and 35 (10.2%) had other 
cancers. There were no significant differences in clinical 
materials for each group (P > 0.05). The baseline charac-
teristics of the patients included were listed in Table 1.
A decline in VAS scores was more obvious in the morphine 
group
After an hour, the results were recorded. In the 
morphine group, VAS scores were reduced from 
65.06  ±  13.27 to 16.82  ±  10.89  mm. In the methyl-
prednisolone group, VAS scores were reduced from 
64.04 ±  12.09 to 25.72 ±  15.03  mm. In the aminophyl-
line group, VAS scores were reduced from 64.43 ± 11.86 
to 31.95 ± 16.00 mm. There were no statistically signifi-
cant differences in the VAS scores between groups before 
treatment (P = 0.820). However, there was a statistically 
significant difference in the VAS scores after intervention 
(P = 0.000; Table 2).
The effective rate was statistically different between the 
three groups
The treatment was deemed to be effective when the 
VAS scores were reduced by at least 50%, such that an 
effective case was defined as ([(VAS score before treat-
ment  −  VAS score after treatment)/VAS score before 
treatment]  ×  100%)  ≥  50%. The effective rate was cal-
culated as follows: (number of effective case/total case 
number)  ×  100%. The effective rates of patients who 
experienced dyspnea relief were 86.44, 62.16, and 49.12% 
in the morphine, methylprednisolone, and aminophyl-
line groups, respectively. There was a statistically differ-
ence between the morphine group and other two groups 
(χ2 = 17.83, P = 0.000 and χ2 = 37.17, P = 0.000 for mor-
phine vs. methylprednisolone and morphine vs. amino-
phylline, respectively) (Table 3).
Table 1 Characteristics of the patients (n = 343)
Characteristic Morphine Methylprednisolone Aminophylline
Patients 118 111 114
Age in years 
(mean)
54.2 53.1 53.7
Sex (M/F) 61/57 54/58 60/54
Diagnoses
 Tumor (n)
 Lung 45 (38.1%) 37 (33.3%) 43 (37.7%)
 Breast 30 (25.4%) 34 (30.6%) 32 (28.1%)
 Colorectal 15 (12.7%) 17 (15.3%) 14 (12.3%)
 Gastric 15 (12.7%) 13 (11.7%) 13 (11.4%)
 Others 13 (11%) 10 (9%) 12 (10.5%)
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Adverse effects
Adverse effects (AEs) are summarized in Table  4. We 
recorded no drug-related deaths and no serious AEs 
that required drug discontinuation. No cases of seri-
ous respiratory depression were observed. No patients 
reported evident side effects after drug intervention 
in the methylprednisolone and aminophylline group. 
In the morphine group, the most frequently observed 
AEs were somnolence and constipation. Roughly 
half of the cases experienced somnolence, and 12 
patients required a dose reduction to ease excessive 
somnolence.
Discussion
Breathlessness, or shortness of breath, refers to discom-
fort and difficulty in breathing. The medical terminology 
for breathlessness is dyspnea or respiratory depression 
(Williams 2006). People describe the feeling of breathless 
in different ways. Patients often use the phrases “short-
ness of breath,” “cannot get enough air,” “out of breath,” 
or “tightness in my chest.” Dyspnea is one major cause of 
suffering in cancer patients, and it impairs the patient’s 
quality of life as severely as cancer pain.
In Western countries, exogenous opioid drugs, such 
as morphine sulfate, are recognized as the first-line of 
therapy in the symptomatic treatment of breathlessness 
in patients with advanced malignant tumors (Williams 
2006; Dy et  al. 2008; Ben-Aharon et  al. 2012; Cheung 
and Zimmermann 2011). In China, corticosteroids and 
bronchodilators are widely used to treat the bronchocon-
striction associated with asthma and chronic obstructive 
pulmonary disease (COPD) (Walters et al. 2014; Nardini 
et al. 2014). These medications can reduce airway inflam-
mation and edema and reduce the sense of effort with 
breathing. Therefore, clinicians empirically apply meth-
ylprednisolone and aminophylline to relief dyspnea in 
patients that have terminal cancer. However, morphine 
is still rarely used by Chinese doctors for the treatment 
of cancer-related dyspnea. Many clinicians are uncertain 
as to which drug might be most effective and whether or 
not morphine should be used to be treat cancer-related 
dyspnea. At present there is a lack of related literature 
that directly compares these three drugs, and there are 
no existing guidelines for the management of dyspnea in 
China.
In this research, 343 patients were divided into three 
groups based on the treatment received. Subcutane-
ous and intravenous routes of administration were used 
in the study, because the ability to swallow declines and 
consciousness often wanes during the last weeks of life. 
Our results showed that morphine was superior to meth-
ylprednisolone and aminophylline for controlling the 
symptoms of cancer-related dyspnea. The VAS scores 
were 16.82 ± 10.89, 25.72 ± 15.03, and 31.95 ± 16.00 mm 
(P  =  0.000) after treatment in the morphine, methyl-
prednisolone, and aminophylline groups, respectively. 
Moreover, the effective rate of morphine was also obvi-
ously higher than that of the other drugs. The symptom 
improvement was more apparent in the morphine treat-
ment group, while patients treated with methylpredniso-
lone and aminophylline usually required repeat doses.
Table 2 Before and after treatment VAS score comparison
VAS visual analogue score
Groups Morphine Methylprednisolone Aminophylline F value P value
VAS score before treatment 65.06 ± 13.27 64.04 ± 12.09 64.43 ± 11.86 0.198 0.820
VAS score after treatment 16.82 ± 10.89 24.58 ± 17.51 31.95 ± 16.00 31.721 0.000
Table 3 Comparison of effective rate between morphine and the other two groups
* Comparison with morphine group
Groups Total number Effective number Effective rate (%) χ2 value P value
Morphine 118 102 86.44
Methylprednisolone 111 69 62.16 17.826 0.000*
Aminophylline 114 56 49.12 37.172 0.000*
Table 4 Adverse events related to the treatments
Adverse events Morphine Methylprednisolone Aminophylline
Somnolence 62 None None
Constipation 55 None None
Nausea/vomiting 28 None 14
Dizziness 19 None None
Flushing 3 11 None
Xerostomia 5 None None
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At the same time, this study implied that adverse 
effects of morphine treatment were generally well toler-
ated, with somnolence and constipation being the most 
common AEs. Neither respiratory depression nor severe 
sedation was observed in the morphine group. In China, 
clinicians, patients, and their families are still reluctant to 
use morphine, because of the fear of respiratory depres-
sion. In fact, there is no need to be overly concerned 
with respiratory depression. Morphine has been widely 
used to treat cancer pain, and the incidence of respira-
tory depression has been proven to be uncommon (Mer-
cadante 2010). Even if respiratory depression were to 
occur, the opioid antagonist naloxone can quickly and 
effectively reverse respiratory depression (Howlett et  al. 
2016; Taylor et al. 2013). There are few reports concern-
ing morphine poisoning deaths, and no evident serious 
adverse effects (respiratory depression) were observed 
in the recent literature concerning the use of morphine 
for alleviating cancer-related dyspnea (Ben-Aharon et al. 
2012).
Morphine is often used to treat severe cancer pain and 
acute heart failure (Nardini et al. 2014; Iakobishvili et al. 
2011). However, the use of morphine is at risk of addic-
tion and respiratory depression (Chidambaran et  al. 
2015). Many physicians and patients are reluctant to 
use morphine for fear of respiratory depression and the 
lack of comprehensive understanding about morphine. 
Hence, in China, morphine is considered to be the con-
traindicated for dyspnea (due to the risk of respiratory 
depression). Additionally, although morphine has been 
prohibited to treat COPD for a long time, it is presently 
the first-line drug used to alleviate breathlessness for 
patients with COPD (Zebraski et  al. 2000; Mahler et  al. 
2010; Verberkt et al. 2016). Increasing numbers of clini-
cal studies support the notion that morphine should be a 
first-line drug that is effective and safe for the treatment 
of dyspnea in terminal cancer. It does not accelerate the 
deterioration of the patient’s condition or hasten death 
(Bonnichon et  al. 2008). The National Comprehensive 
Cancer Network (NCCN) clinical practice guidelines 
in oncology palliative care recommend that opioids are 
one class of effective drugs available for cancer-related 
dyspnea, especially those patients who have a shorter life 
expectancy. Morphine sulfate, a representative opioid is 
effective in alleviating the symptoms of breathlessness, 
decreasing the ventilator response to hypoxia and hyper-
capnia, while decreasing oxygen consumption at rest and 
exercise (Williams 2006).
In contrast to vision, hearing, and pain, the neurophysi-
ology of cancer-related dyspnea is far less understood. 
The reason why morphine relieves dyspnea may include 
the following aspects. Dyspnea in cancer patients is usu-
ally associated with the degree of anxiety, fear, panic, and 
depression, which can be improved by morphine arising 
to be mixed undisturbedly demulcent action (Polanski 
et al. 2016). Morphine probably acts both by depressing 
spontaneous respiratory drive and by modulating cortical 
activity, much like what happens with morphine treat-
ment for pain. Current studies have shown that dyspnea 
and pain are both influenced by a common central nerv-
ous control area; there is speculation that the mechanism 
of morphine-mediated dyspnea relief is similar to the 
mechanisms that alleviate pain (Clemens et al. 2008). In 
addition, morphine may also play a role in decreasing 
the sensitivity to dyspnea, improving the body’s toler-
ance and cardiovascular function, reducing the ventila-
tor response to hypoxia and hypercapnia (Zebraski et al. 
2000). It is possible that the influence of these different 
mechanisms varies in different patients.
Undoubtedly, it is also extremely important to treat the 
underlying cause of the breathlessness, such as a reduc-
tion hydrothorax and ascites (Williams 2006; Dy et  al. 
2008; Bausewein et al. 2008). Moreover, benzodiazepines 
(BZDs) may be considered as a second- or third-line 
treatment in patients when dyspnea is not relieved by 
opioids, particularly if anxiety is a significant coexisting 
symptom (Clemens and Klaschik 2011).
The present work has several limitations. First, this 
study is a retrospective study. Data collection relied on 
medical record review, and the documentation may have 
been limited. Second, our sample size is not large enough 
to definitively state that morphine is superior to other 
treatments for dyspnea. Third, there may be the poten-
tial for confounding factors, such as psychosocial and 
patient factors that were not measured in the context of 
this study, but could impact our results.
Conclusions
Morphine is generally safe and significantly more effective 
than methylprednisolone and aminophylline in manage-
ment of dyspnea for terminal cancer patients. This treat-
ment could significantly help improve the quality of life in 
such patients, although further research is needed to detail 
and clarify the efficacy of morphine for the treatment of 
dyspnea in patients with advanced malignant tumors. It 
is our opinion that Chinese oncologists should consider 
changing their static/conservative views on morphine, and 
strive towards understanding the special role of morphine 
in the management of cancer-related dyspnea to better 
control/minimize suffering in terminal cancer patients.
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